Skip to Main Content

Paper Details

Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity.
Nature Communications
10
2022
ACVR1C, INHBE, abdominal obesity, activin E, activin receptor, activins, cardiometabolic disease, coronary heart disease, exome sequences, genetic variants, hepatokine gene, hepatokine gene INHBE, in-frame deletion, pLOF variant, type 2 diabetes
Author NameAffiliation
Aimee M DeatonAlnylam Pharmaceuticals
Aditi DubeyAlnylam Pharmaceuticals
Lucas D WardAlnylam Pharmaceuticals
Peter DornbosBroad Institute
Peter DornbosBoston Children's Hospital
Peter DornbosHarvard Medical School
Jason FlannickBroad Institute
Jason FlannickBoston Children's Hospital
Jason FlannickHarvard Medical School
Elaine YeeAlnylam Pharmaceuticals
Simina TicauAlnylam Pharmaceuticals
Leila NoetzliAlnylam Pharmaceuticals
Margaret M ParkerAlnylam Pharmaceuticals
Rachel A HoffingAlnylam Pharmaceuticals
Carissa WillisAlnylam Pharmaceuticals
Mollie E PlekanAlnylam Pharmaceuticals
Aaron M HollemanAlnylam Pharmaceuticals
Gregory HinkleAlnylam Pharmaceuticals
Kevin FitzgeraldAlnylam Pharmaceuticals
Akshay K VaishnawAlnylam Pharmaceuticals
Paul NioiAlnylam Pharmaceuticals
  • 1 - 21

Datasets

Release 1.2